Premature Ventricular Contractions (PVCs) and Blood Pressure Control

• Status: Terminated
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if reduction in premature ventricular contraction (PVC) burden results in a decrease in blood pressure, sympathetic outflow, plasma catecholamines and an improvement in baroreflex gain. Flecainide will be used for PVC suppression in a randomized, double-blinded, crossover fashion.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Wisconsin, Madison
• Treatments: Flecainide

Criteria

Inclusion Criteria:

• Frequent symptomatic premature ventricular contractions (PVCs) (>10% of total QRSs on a 24-hour Holter)

• Willingness to participate in research

Exclusion Criteria:

• Age > 65 years old

• Pacemaker implantation

• Implantable cardioverter defibrillator implantation requiring pacing

• Sick sinus syndrome

• Atrio-ventricular (AV) block

• Left ventricular dysfunction defined as left ventricular ejection fraction < 50%

• History of myocardial infarction or coronary artery disease

• Severe left ventricular hypertrophy (wall thickness > 1.5 cm by echocardiography performed within 3 months from enrollment)

• Severe liver dysfunction

• Creatinine clearance of 35 mL/min/1.73 square meters or less

• Pregnancy

• Known hypersensitivity to the drug

• QRS duration > 120 ms

• Recent change in blood pressure medication within 30 days of enrollment